



Universiteit
Leiden

The Netherlands

Defining optimal oncolytic virus treatment and diagnostics in high risk melanoma patients

Stahlie, E.H.A.

Citation

Stahlie, E. H. A. (2023, April 19). *Defining optimal oncolytic virus treatment and diagnostics in high risk melanoma patients*. Retrieved from <https://hdl.handle.net/1887/3594222>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3594222>

Note: To cite this publication please use the final published version (if applicable).

**Defining optimal oncolytic virus treatment and
diagnostics in high risk melanoma patients**

Emma Stahlie

This printing of this research was financially supported by Chipsoft, LUMC, The Netherlands Cancer Institute, and SBOH.

Provided by thesis specialist Ridderprint, ridderprint.nl

Printing: Ridderprint

Layout and cover design: Birgit Vredenburg, persoonlijkproefschrift.nl

ISBN: 978-94-6483-019-4

Copyright 2023 © Emma Stahlie

The Netherlands. All rights reserved. No parts of this thesis may be reproduced, stored in a retrieval system or transmitted in any form or by any means without permission of the author.

Defining optimal oncolytic virus treatment and diagnostics in high risk melanoma patients

Proefschrift

ter verkrijging van

de graad van doctor aan de Universiteit Leiden,

op gezag van rector magnificus prof.dr.ir. H. Bijl,

volgens besluit van het college voor promoties

te verdedigen op woensdag 19 april 2023

klokke 10.00 uur

door

Emma Hendrika Anniemarie Stahle

geboren te Rome, Italie

in 1993

Promotor:

Prof. Dr. M.W.J.M Wouters

Copromotor:

Assoc. Prof. Dr. A.C.J. van Akkooi

Melanoma Institute Australia, University
of Sydney, Royal Prince Alfred Hospital

Promotiecommissie:

Prof. Dr. J.A. van der Hage

Dr. H.W. Kapiteijn

Prof. Dr. M.W. Bekkenk

Prof. Dr. C. Verhoef

Amsterdam Universitair Medisch
Centrum

Erasmus Medisch Centrum

TABLE OF CONTENTS

Chapter 1.	General introduction and outline of the thesis	7
PART I -	ADVANCES AND FUTURE DIRECTIONS OF T-VEC	17
Chapter 2.	T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model. <i>Cancer Immunology and Immunotherapy 2021</i>	19
Chapter 3.	Validation and expansion of clinical prediction model for response to T-VEC in stage IIIB-IVM1a melanoma patients. <i>Annals of Surgical Oncology 2021</i>	39
Chapter 4.	Single agent Talimogene Laherparepvec (T-VEC) for stage IIIB-IVM1c melanoma patients: a literature review and meta-analysis. <i>Critical Reviews in Oncology / Hematology 2022</i>	55
Chapter 5.	False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T-VEC). <i>Journal of Surgical Oncology 2021</i>	77
Chapter 6.	Dermoscopy as response evaluation tool for cutaneous malignant melanoma metastases treated with Talimogene Laherparepvec: a prospective feasibility study. <i>European Academy of Dermatology and Venereology 2022</i>	87
PART II -	REFINING TREATMENT AND DIAGNOSTICS IN HIGH RISK MELANOMA	101
Chapter 7.	The use of FDG-PET/CT to detect early recurrence after resection of high-risk stage III melanoma. <i>European Journal of Surgical Oncology 2020</i>	103
Chapter 8.	The value of lymph node ultrasound and whole body 18F-FDG PET/CT in stage IIB/C melanoma patients prior to SLNB. <i>Journal of Surgical Oncology 2020</i>	123
Chapter 9.	General discussion	139
Chapter 10.	Summary	151
Appendices	Samenvatting	155
	List of publications	159
	Dankwoord	162
	Curriculum Vitae	164